NL-OMON33532已完成不适用
A randomized, double-blinded, placebo-controlled, single centre, phase I study of the safety of escalating single intravenous doses of NI-0801 in healthy volunteers. - Phase I study to investigate the safety of escalating i.v. doses of Ni-0801
ovImmune S.A.0 个研究点目标入组 30 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •written consent • men between 18 and 50 years old • physically en mentally healthy • normal BMI
排除标准
- •smoking • drugs and/or alcohol abuse • surgery within 3 months prior to study • use concomitant medication in two weeks prior to study • participation in another clinical study in 3 months prior to this study • Blood donation in 3 months prior to this study • positive for Hepatitis B, C or HIV • positive tuberculosis test • Vaccination within 6 weeks prior to start study medication
研究者
相似试验
进行中（未招募）
不适用
Investigating the effectiveness and safety of gelatin tannate and tyndallized acid lactic bacteria in adult patients with chronic diarrhoea with dysbiosisISRCTN63068134oventure S.L.190
招募中
1 期
‘A clinical trial to test the safety and immune responses from the BG505 SOSIP.664 gp140 HIV vaccine in development’.PACTR202006565880683IAVI60
尚未招募
不适用
A randomized, double-blinded, placebo-controlled, crossover study of 5-aminolevulinic acid in the prevention of migraineMigraineJPRN-UMIN000019084Department of neurosurgery, Osaka Medical college50
尚未招募
2 期
The CANBACK trial, to determine the efficacy of oral cannabidiol, when compared to placebo, as an adjunct for the treatment of acute non-traumatic low back pain.Back painACTRN12618000487213Dr Bronwyn Bebee100
招募中
不适用
A randomized, double-blinded, placebo-controlled, dose-escalation phase 1 clinical trial to evaluate the safety and immunogenicity of recombinant HIV-1 envelope protein BG505 SOSIP.GT1.1 gp140 Vaccine, Adjuvanted in healthy, HIV-uninfected adultsAIDSHIV10047438NL-OMON54857International AIDS Vaccine Initiative (IAVI)18